(E)-3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylaldehyde | 290820-47-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂醛
• 英文名称: (E)-3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylaldehyde
• 英文别名: Coniferyl aldehyde, TBDMS derivative；(E)-3-[4-[tert-butyl(dimethyl)silyl]oxy-3-methoxyphenyl]prop-2-enal
• CAS: 290820-47-2
• 化学式: C₁₆H₂₄O₃Si
• 分子量: 292.45
• InChiKey: RTJRBYNXAVSFEL-BQYQJAHWSA-N

物化性质

• 熔点：
  79 °C
• 沸点：
  371.8±37.0 °C(Predicted)
• 密度：
  0.994±0.06 g/cm3(Predicted)
• 保留指数：
  2114.7

计算性质

• 辛醇/水分配系数(LogP)：
  4.29
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylaldehyde 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-[4-(tert-Butyl-dimethyl-silanyloxy)-3-methoxy-phenyl]-hexan-3-ol
  参考文献：
  名称：

  Chain-Branched acyclic phenethylthiocarbamates as vanilloid receptor antagonists

  摘要：

  A series of acyclic phenethylthiocarbamate derivatives have been synthesized, and their antagonist effect against vanilloid receptor tested. Chain branching led to a significant change in antagonist activity of the parent molecule. Ethyl-branched le showed a 6.3 muM Of IC50 value in Ca-45(2+)-influx assay. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00178-1
• 作为产物：
  描述：

  香草醛 在 咪唑 、 manganese(IV) oxide 、 sodium hexamethyldisilazane 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 83.0h， 生成 (E)-3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylaldehyde
  参考文献：
  名称：

  [EN] NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES
  [FR] AGENTS NEUROPROTECTEURS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES

  摘要：

  化合物I的化学式对治疗神经退行性疾病有用：I，其中R1是一个C1-12有机基团；是一个含有5到12个环原子和最多三个异原子（分别选自N、O、S和Se）的C1-12杂环环系统；R2是C1-12有机基团；R7、R8分别独立地是氢（H）、羟基、羰基（即酮基）、C1-8烷基、C1-8烷氧基、C2-8烯基、C2-10炔基、C5-7环烷基、C5-7环烯基、卤素、C1-4醛基，或-NR4q，其中R4是H、C1-8烷基、C2-8烯基、C4-8环烷基、C4-8环烯基或C6-10芳基；o为0、1、2、3或4；A是一个C6-12芳基、C5-12杂芳基，或一个可选择地取代的3-羟基吡啶-4(1H)-酮；p是一个从1到6的整数；Zm不存在或是一个二价连接基团；m是表示Z重复次数的整数。

  公开号：

  WO2014085600A1

文献信息

• Modular synthesis of (<i>E</i>)-cinnamaldehydes directly from allylarenes <i>via</i> a metal-free DDQ-mediated oxidative process
  作者：Ting-Ting Xu、Tao-Shan Jiang、Xiao-Lan Han、Yuan-Hong Xu、Jin-Ping Qiao

  DOI：10.1039/c8ob01469h

  日期：——

  An efficient synthesis of (E)-cinnamaldehydes by a metal-free DDQ-mediated oxidative transformation of allylarenes was developed. The protocol provides a practical method to prepare diverse (E)-cinnamaldehydes with broad functional group tolerance in good to excellent yields, including easy access to natural products randainal and geranyloxy sinapyl aldehyde from plant extracts. Finally, the mechanism

  通过无金属的DDQ介导的烯丙基芳烃的氧化转化，可以有效合成（E）-肉桂醛。该协议提供了一种实用的方法来制备具有宽泛的官能团耐受性的多种（E）-肉桂醛，并具有良好的优异收率，包括从植物提取物中容易获得天然产物蓝丹醛和香叶基氧基芥子醛。最后，提出了单电子转移过程的机理。
• A Mesoporous-Silica-Immobilized Oxovanadium Cocatalyst for the Lipase-Catalyzed Dynamic Kinetic Resolution of Racemic Alcohols
  作者：Masahiro Egi、Koji Sugiyama、Moriaki Saneto、Ryosuke Hanada、Katsuya Kato、Shuji Akai

  DOI：10.1002/anie.201208988

  日期：2013.3.25

  V for resolution: A new oxovanadium catalyst (V‐MPS; see scheme) immobilized in the pores of mesoporous silica has been developed. The combined use of V‐MPS and lipases achieved the dynamic kinetic resolution of a wide range of racemic alcohols (1 or 2) to produce optically active esters 3 in high chemical and optical yields. The paired catalysts retained high catalytic activity when reused up to six

  用于分离的V：已经开发了一种固定在介孔二氧化硅孔中的新型氧钒催化剂（V‐MPS;参见方案）。V‐MPS和脂肪酶的组合使用可实现多种外消旋醇（1或2）的动态动力学拆分，从而以高化学和光学收率生产光学活性酯3。当重复使用多达六次时，成对的催化剂保持了高催化活性。
• Suppression of Inducible Nitric Oxide Synthase Expression by Yakuchinones and Their Analogues
  作者：Hwa Jin Lee、Ji Sun Kim、Joung Wha Yoon、Hee-Doo Kim、Jae-Ha Ryu

  DOI：10.1248/cpb.54.377

  日期：——

  Analogues of yakuchinones were synthesized as inhibitors of nitric oxide production in lipopolysaccharide-activated macrophage cell line, RAW 264.7 cells. We prepared stronger inhibitors than the original natural molecules, yakuchinones A and B reported from Alpinia oxyphylla. From the limited structural activity relation study of analogues, we concluded that the optimal length of linker between two aryl groups and the presence of enone moiety in the linker were identified as essential for the activity. The IC50 value of the most potent structure was 0.92 μM. The active analogues suppressed the expression of inducible nitric oxide synthase protein and mRNA.

  合成了类黄酮化合物作为抑制脂多糖激活的巨噬细胞系RAW 264.7细胞中一氧化氮产生的抑制剂。我们制备了比来自毛竹（Alpinia oxyphylla）的天然分子黄酮A和B更强的抑制剂。通过对类化合物的有限结构活性关系研究，我们得出结论：维持两个芳基之间的连接链的最佳长度以及连接链中存在烯酮基团对活性至关重要。最有效结构的IC50值为0.92μM。活性类化合物抑制了诱导型一氧化氮合酶蛋白及其mRNA的表达。
• Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
  申请人：——

  公开号：US20030203944A1

  公开（公告）日：2003-10-30

  The present invention relates to an antagonist against vanilloid receptor and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fevescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及针对辣椒素受体的拮抗剂以及含有该拮抗剂的药物组合物。作为与辣椒素受体活性相关的疾病，可以列举出疼痛、急性疼痛、慢性疼痛、神经痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病性神经病、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合症、哮喘或慢性阻塞性肺疾病等呼吸道疾病、皮肤、眼睛或粘膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病。本发明提供了用于预防或治疗这些疾病的药物组合物。
• NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：WAYNE STATE UNIVERSITY

  公开号：US20150299180A1

  公开（公告）日：2015-10-22

  A compound having formula I is useful for treating a neurodegenerative disease: R 1 is an C 1-12 organyl group; is a C 1-12 heterocyclic ring system containing 5 to 12 ring atoms and up to three heteroatoms individually selected from the group consisting of N, O, S, and Se; R 2 are C 1-12 organyl groups; R 7 , R 8 are each independently, hydrogen (H), hydroxyl, oxo (i.e., carbonyl), C 1-8 alkyl, C 1-8 alkoxyl, C 2-8 alkenyl, C 2-10 alkynyl, C 5-7 cycloalkyl, C 5-7 cycloalkenyl, halo, C 1-4 aldehyde, or —NR 4 q where R 4 is H, C 1-8 alkyl, C 2-8 alkenyl, C 4-8 cycloalkyl, C 4-8 cycloalkenyl, or C 6-10 aryl; o is 0, 1, 2, 3, or 4; A is a C 6-12 aryl group, C 5-12 heteroaryl group, or an optionally substituted 3-hydroxypyridin-4(1H)-one; p is an integer from 1 to 6; and Z m is absent or a divalent linking moiety; and m is an integer representing the number of time Z is repeated.

  化合物I的化学式对治疗神经退行性疾病有用：R1是C1-12有机基团；是含有5到12个环原子和最多三个异原子（选自N、O、S和Se的群体）的C1-12杂环环系统；R2是C1-12有机基团；R7、R8各自独立地是氢（H）、羟基、氧代（即羰基）、C1-8烷基、C1-8烷氧基、C2-8烯基、C2-10炔基、C5-7环烷基、C5-7环烯基、卤素、C1-4醛基或—NR4q，其中R4是H、C1-8烷基、C2-8烯基、C4-8环烷基、C4-8环烯基或C6-10芳基；o为0、1、2、3或4；A是C6-12芳基、C5-12杂芳基或可选地取代的3-羟基吡啶-4（1H）-酮；p为1到6的整数；Zm是缺席或二价连接基；m是代表Z重复次数的整数。